[CAS NO. 50924-49-7] Mizoribine

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [50924-49-7]

Catalog

HY-17470

Brand

MCE

CAS

50924-49-7

DESCRIPTION [50924-49-7]

Overview

MDL	MFCD00057221
Molecular Weight	259.22
Molecular Formula	C9H13N3O6
SMILES	OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C(O)=C(C(N)=O)N=C2)O1

For research use only. We do not sell to patients.

3 Publications Citing Use of MCE

Summary

Mizoribine (NSC 289637), an imidazole nucleoside, inhibits HCV RNA replication with IC ₅₀ of approximately 100 μM for anti-HCV activity. Immunosuppressant ^[1] . Mizoribine, an IMPDH inhibitor, inhibits replication of SARS-CoV with IC ₅₀ s of 3.5 μg/mL and 16 μg/mL for SARS-CoV Frankfurt-1 and SARS-CoV HKU39849, respectively ^[2] .

IC50 & Target

HCV ^[1] ; IMPDH; SARS-CoV ^[2]

In Vitro

Mizoribine, isolated from culture medium of the mold Eupenicillium brefeldianum M-2166, acts as an immunosuppressant which exerts its effects without severe side effects ^[1] .
Mizoribine is an inosine-5′-monophosphate dehydrogenase (IMPDH) inhibitorused for renal transplantation, autoimmune diseases and steroid-resistant nephrotic syndrome ^[2] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Mizoribine suppresses collagen-induced arthritis. Mizoribine (10, 20 and 50 mg/kg; Administered orally 5 days a week for 12 weeks) reduces the arthritis score in a dose-dependent fashion, showing significant suppression, even at a dose of 10 mg/kg ^[3] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male DBA/1 J mice with collagen-induced arthritis ^[3]
Dosage:	10, 20 and 50 mg/kg
Administration:	Administered orally 5 days a week for 12 weeks
Result:	Showed dose-dependency of the suppressive effect.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT02373202	Sanofi\|Regeneron Pharmaceuticals	Rheumatoid Arthritis	February 2015	Phase 3
NCT02257697	Asahi Kasei Pharma Corporation	Nephrotic Syndrome	November 2014	Phase 3
NCT02256150	Asahi Kasei Pharma Corporation	Lupus Nephritis	November 2014	Phase 3
NCT05293704	Lee´s Pharmaceutical Limited	Kidney Transplant Recipients\|BK Virus	May 1, 2022	Phase 4

Appearance

Solid

Source

Eupenicillium brefeldianum M-2166

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 125 mg/mL ( 482.22 mM ; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.8577 mL	19.2886 mL	38.5773 mL
5 mM	0.7715 mL	3.8577 mL	7.7155 mL
10 mM	0.3858 mL	1.9289 mL	3.8577 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 2.5 mg/mL (9.64 mM); Clear solution
2.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.5 mg/mL (9.64 mM); Clear solution
3.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 2.5 mg/mL (9.64 mM); Clear solution

* All of the co-solvents are available by MCE.

References

Synonyms

1H-Imidazole-4-carboxamide, 5-hydroxy-1-β-D-ribofuranosyl-

5-Hydroxy-1-β-D-ribofuranosyl-1H-imidazole-4-carboxamide

Bredinin

Mizoribine

β-Bredinin

HE 69

NSC 289637